![](https://investorshub.advfn.com/uicon/32556.png?cb=1490101632)
Saturday, March 20, 2010 10:19:51 AM
Avid figures from SK’s 2-9-10 BIO-CEO talk - 12 mos. ended 10-2009 (Q2):
• 18.1mm - 3rd-Party CMO
• 4.1mm - Gov’t (DTRA/TMTI)
• 11.7mm - Peregrine Internal
= $33.9mm - Total Avid Services for 12mos. ended 10-2009
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=46469037
Avid figures from SK’s 3-17-10 ROTH talk - 12 mos. ended 1-2010 (Q3):
• 15.3mm - 3rd-Party CMO
• 8.3mm - Gov’t (DTRA/TMTI)
• 8.8mm - Peregrine Internal
= $32.4mm - Total Avid Services for 12mos. ended 1-2010
http://tinyurl.com/ye9v7jq
You’re right, that IS an awful lot of Bavi Juice (or FH-Bavi Juice) to produce for the Gov’t in this last quarter. “Animal Rule” progress picking up steam?? Man, that’d be nice…
SK SAID THIS ABOUT POTENTIAL BAVI APPROVAL FOR VHF ON 2-9-10 (BIO-CEO):
SK 2-9-10, Slide8: “Innovative Science Portfolio. . . And then, we have another interesting opportunity from a product dev. standpoint, and that is Bavi for the treatment of VHF. So, this pathway for product approval will be quite different than the Ph1-Ph2 and then Pivotal trial type approach to getting drugs approved. But rather we’ll probably end up going thru an Animal Rule to eventually get approval.”
http://tinyurl.com/ykxznha
AND THEN ON 3-17-10, SK EXPANDED ON GOVT/VHF POSSIBILITIES A BIT MORE:
SK 3-17-10, Slide7: “…And then we have a real interesting part of the portfolio, which is our Bavituximab Viral Hemorrhagic Fever (VHF) Infection program. This is completely funded by the DOD in evaluating Bavi for the treatment or prevention of VHF. What’s interesting about this compound is this would not take a typical Phase1-2-3 approval approach, but rather likely go thru the FDA’s “Animal Rule”, which means that it basically would have animal efficacy data, combined with human safety data, which we’re obviously generating a lot of, and then it would be applied for approval based on those 2 things. So this could be a much shorter entry point into an actual product that could be acquired by the gov’t to stockpile as part of its biodefense efforts.”
http://tinyurl.com/ye9v7jq
= = = = = = = = = = = = = IT ALL GOES BACK TO THIS:
BIOWORLD Today - Jul. 03, 2008 (2 days after the DTRA VHF Award):
… “Solid tumors will more than likely be the first indication Peregrine seeks, he [CEO Steve King] noted. However, because of the expedited process in developing products under the govt's animal efficacy rule, the viral hemorrhagic fevers indication potentially could be the first approved use for Bavituximab”…
http://tinyurl.com/5kr6xk
BACKGROUND:
7-1-08: PPHM Awarded 5-yr $44mm DTRA/TMTI Contract for Anti-PS vs. Hemorrhagic Fevers http://tinyurl.com/5dxpup
…”Contract to test & develop bavituximab and an equivalent fully human antibody as potential broad-spectrum treatments for viral hemorrhagic fever infections”
7-3-08 BioWorld Today article on PPHM’s DTRA Deal: http://tinyurl.com/5kr6xk
10-2009: U-PITT REPORT FOR DARPA ON BIOLOGICS DEMAND REF’S BAVI:
Pg.39:
Table: Ensuring Biologics Advanced Dev. & Mfg. Capability for the USGovt: A Summary of Key Findings & Conclusions
Agent: “Broad Spectrum Viral Inhibitor” (#3 of 13)
Class: Therapeutic
DoD(Regimens/TED): 100,000 (C)6
HHS(Regimens): 100,000 (C)6
Note (C): No defined requirement, partial info. provided during interviews
Note#6: “Demand is modeled on products like Bavituximab under development by Peregrine Pharmaceuticals Inc. This monoclonal product targets aminophospholipids exposed on surface of host cells infected with enveloped viruses. Minimum estimated requirement for broad-spectrum biologic derived anti-viral based on PHEMCE (Public Health Emergency Medical Countermeasures Enterprise) implementation plan prioritization of broad-spectrum, DoD R&D funding priorities, and interviews with HHS & DoD personnel. It is likely the demand would be higher, but estimate is based on the consensus of the interviewees.”
Pg.150:
Agent: “Broad Spectrum Viral Inhibitor”
Class: Therapeutic
• Dose-Stockpile= 200,000
• Dose-Surge= 5,328,000
• Fill-Stockpile= 16,667
• Fill-Surge= 1,065,600
http://tinyurl.com/yaefb4j
11-18-09: PPHM PRESENTS ANTIPS/VHFS PRE-CLIN. DATA AT DTRA/TMTI CONF.
“Researchers presented interim data from Peregrine's multi-year program to assess the company's PS-targeting antibodies as broad-spectrum agents for the treatment of viral hemorrhagic fevers, a potential biodefense threat. The studies evaluated the activity of Peregrine's PS-targeting antibodies against representatives of major VHF virus families. In these studies, researchers confirmed broad spectrum PS-targeting antibody binding to VHF viral particles and also demonstrated that Peregrine's PS-targeting antibodies bind to mammalian cells infected with hemorrhagic fever viruses. Initial pharmacokinetic and dosing studies also showed that the PS-targeting antibodies are sustainable in the blood at therapeutically relevant concentrations. Importantly, initial antiviral efficacy studies reported at the conference were encouraging, showing that a single dose of a PS-targeting antibody increased the survival of hamsters infected with lethal doses of viruses from two different VHF virus families. Based on these positive findings, additional efficacy studies, including repeat dose and combination therapy studies, are now underway.”
http://tinyurl.com/ycrrwub
More on Bavi’s “Animal Rule” possibilities:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=47765619
Recent CDMO News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/16/2024 11:50:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/16/2024 11:48:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/15/2024 08:40:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/12/2024 08:30:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:02:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:02:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:01:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:01:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:00:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:00:45 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/11/2024 12:23:26 AM
- Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2024 • GlobeNewswire Inc. • 07/02/2024 08:05:04 PM
- Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2024, After Market Close on July 2, 2024 • GlobeNewswire Inc. • 07/01/2024 11:00:21 AM
- Avid Bioservices Earns Committed Badge from EcoVadis for Sustainability Performance • GlobeNewswire Inc. • 05/23/2024 12:05:46 PM
- Avid Bioservices to Participate at Upcoming Investor Conferences • GlobeNewswire Inc. • 05/07/2024 08:05:11 PM
- Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 04/24/2024 09:25:33 PM
- Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-Q • GlobeNewswire Inc. • 03/20/2024 11:00:10 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 11:30:11 AM
- Avid Bioservices Announces Pricing of Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/07/2024 04:58:48 AM
- Avid Bioservices Announces Proposed Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/06/2024 09:32:07 PM
- Avid Bioservices Announces Certain Preliminary Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 03/06/2024 09:31:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:30:18 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/26/2024 09:57:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2024 12:34:35 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:39:18 AM
FEATURED Southern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project • Jul 25, 2024 8:00 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM